Form 4: Invivyd Director Christine Lindenboom Acquires Stock Options

Christine Lindenboom, a director of Invivyd, Inc., was granted stock options to purchase 50,000 shares of common stock.

Summary

• On May 20, 2025, Christine Lindenboom, a director of Invivyd, Inc., was granted stock options to purchase 50,000 shares of common stock at an exercise price of $0.8092.
• The options vest in full on the earlier of May 20, 2026, or the date of the Issuer's 2026 Annual Meeting of Stockholders, contingent upon continuous service through the vesting date.
• Following the transaction, Lindenboom directly owns 50,000 derivative securities.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive. The granting of stock options is a common practice and suggests confidence in the company's future, but it's not a major event.

Positives

• The granting of stock options to a director aligns their interests with those of the shareholders, potentially incentivizing them to work towards the company's success.

Industry Context

This is a standard practice for incentivizing board members in publicly traded companies, particularly in the biotech industry where long-term growth is prioritized.

Comparison to Industry Standards

• Stock option grants to directors are a common practice in publicly traded companies, especially in the biotechnology sector.
• Companies like Moderna and BioNTech also use stock options as part of their compensation packages for directors and executives to align their interests with shareholders.
• The vesting schedule and exercise price are typical for such grants, often tied to continued service and company performance.

Stakeholder Impact

• Shareholders may view the granting of stock options positively as it aligns the director's interests with the company's long-term success.
• Employees may see this as a sign of confidence in the company's future.

Key Dates

Keywords

Invivyd, Lindenboom, Stock Options, Director, Form 4, Beneficial Ownership, IVVD